Zobrazeno 1 - 10
of 147
pro vyhledávání: '"RUNX1-RUNX1T1"'
Publikováno v:
Alexandria Journal of Medicine, Vol 60, Iss 1, Pp 282-289 (2024)
Introduction Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of immature myeloid cells. Among the genetic alterations in AML, the RUNX1- RUNX1T1 fusion, resulting from the t (8; 21) (q22; q
Externí odkaz:
https://doaj.org/article/a8afefcf9d974e1a9ddc5d5ce50dca6b
Autor:
Wenwen Guo, Xin Liu, Mingyang Wang, Jia Liu, Yigeng Cao, Yawei Zheng, Weihua Zhai, Xin Chen, Rongli Zhang, Qiaoling Ma, Donglin Yang, Jialin Wei, Yi He, Aiming Pang, Sizhou Feng, Mingzhe Han, Erlie Jiang
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTObjectives To determine the impact of pretransplant measurable residual disease (pre-MRD) and the efficacy of maintenance therapy in t(8;21) acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (allo-HCT).
Externí odkaz:
https://doaj.org/article/401b605a118745afb095c03621b1a483
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-12 (2021)
Abstract Background Acute myeloid leukemia (AML) with the t(8;21)(q22;q22) chromosomal translocation is among the most common subtypes of AML and produces the AML1-ETO (RUNX1-ETO, RUNX1-RUNX1T1) oncogenic fusion gene. AML1-ETO functions as an aberran
Externí odkaz:
https://doaj.org/article/97aa952932a64c95aa998f264c9dbc5e
Autor:
Guan-hua Hu, Yi-fei Cheng, Ai-dong Lu, Yu Wang, Ying-xi Zuo, Chen-hua Yan, Jun Wu, Yu-qian Sun, Pan Suo, Yu-hong Chen, Huan Chen, Yue-ping Jia, Kai-yan Liu, Wei Han, Lan-ping Xu, Le-ping Zhang, Xiao-jun Huang
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Pediatric acute myeloid leukemia (AML) with t(8;21) (q22;q22) is classified as a low-risk group. However, relapse is still the main factor affecting survival. We aimed to investigate the effect of allogeneic hematopoietic stem cel
Externí odkaz:
https://doaj.org/article/b4dc714a28e140b080eb6251de92151d
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Acute myeloid leukemia (AML) patients who develop hematological relapse (HR) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) generally have dismal clinical outcomes. Measurable residual disease (MRD)-directed preemptive intervent
Externí odkaz:
https://doaj.org/article/e64f66d7936d4aa38e0c346aae19bd42
Autor:
Shuang Fan, Meng-Zhu Shen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Su Zhao, Ya-Zhen Qin, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to
Externí odkaz:
https://doaj.org/article/c6e920f025d44c429506b2d8a36739a1
Autor:
Lu Yang, Wen‐Min Chen, Feng‐Ting Dao, Yan‐Huan Zhang, Ya‐Zhe Wang, Yan Chang, Yan‐Rong Liu, Qian Jiang, Xiao‐Hui Zhang, Kai‐Yan Liu, Xiao‐Jun Huang, Ya‐Zhen Qin
Publikováno v:
Cancer Medicine, Vol 8, Iss 12, Pp 5459-5467 (2019)
Abstract Acute myeloid leukemia (AML) with t(8;21) is a heterogeneous disease. Although the detection of minimal residual disease (MRD), which is indicated by RUNX1‐RUNX1T1 transcript levels, plays a key role in directing treatment, risk stratifica
Externí odkaz:
https://doaj.org/article/8133eeceecc54d118380ccc021c99bbc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ya-Zhen Qin, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Wei Han, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yao Chen, Xiao-Dong Mo, Xiao-Su Zhao, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-9 (2017)
Abstract Background The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in pat
Externí odkaz:
https://doaj.org/article/9dae2515845f42518f311c97c5539846